CClinicalTrials.gg
TerminatedNCT02689635SALTUpdated Apr 22, 2021

Low Sodium vs. Regular Diet in Patients Admitted for Heart Failure

An interventional study of Sodium Restricted Diet and Regular Diet in Heart Failure, sponsored by Maya Guglin. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-22.

Sponsored by Maya Guglin · Not applicable, Interventional, and Prevention

Why this study was terminated
PI transferred to a new institution
Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients over 18 years of age, admitted to the hospital with HF exacerbation, will be eligible for randomization to low salt or regular diet. Laboratory tests are routinely obtained on admission and on the day (or the day before) of discharge (comprehensive metabolic panel and NT-proBNP) and will be recorded for the study. Daily weights are routinely recorded, and intake/output will be monitored. At discharge, a Diet Acceptability Questionnaire will be performed.

After the discharge, participants will return for follow-up visits as needed for clinical indications. Our study coordinator will document changes of symptoms, changes in therapies, and capture clinical events like unscheduled hospital visits or visits to the Emergency Room. Once during the study patients will be asked about their specific food consumption on a prior day, and the Sodium content will be estimated. The final visit will occur in a year (approximately 11-13 months after enrollment). Weight, other vital signs, CMP, BNP, and Diet Acceptability Questionnaire quality of life questionnaire will be collected at this point, if clinically indicated.

The majority of study information will be collected from routine care for standard clinical indications. The only components added for study purpose are Diet Acceptability Questionnaire and collection of the information on consumed foods.

Read the detailed description

This study will include patients over 18 years of age, admitted to the hospital with HF exacerbation, will be eligible for randomization to low salt or regular diet. Laboratory tests are routinely obtained on admission and on the day (or the day before) of discharge (comprehensive metabolic panel and NT-proBNP) and will be recorded for the study. Daily weights are routinely recorded, and intake/output will be monitored. At discharge, a Diet Acceptability Questionnaire will be performed.

After the discharge, participants will return for follow-up visits as needed for clinical indications. Our study coordinator will document changes of symptoms, changes in therapies, and capture clinical events like unscheduled hospital visits or visits to the Emergency Room. Once during the study patients will be asked about their specific food consumption on a prior day, and the Sodium content will be estimated. The final visit will occur in a year (approximately 11-13 months after enrollment). Weight, other vital signs, CMP, BNP, and Diet Acceptability Questionnaire quality of life questionnaire will be collected at this point, if clinically indicated.

The majority of study information will be collected from routine care for standard clinical indications. The only components added for study purpose are Diet Acceptability Questionnaire and collection of the information on consumed foods.The number of total days in the hospital for heart failure throughout the year will be compared between the arms.

02

Conditions studied

  • Heart Failure

Browse trials for

03

In context

Heart Failure

5,697 studies on the registry are indexed under Heart Failure; 1,219 are open to participants now.

This study's enrollment of 13 is below the median of 72 across 3,733 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Maya Guglin is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ≥ 18 years of age
  • Hospital admission for principal diagnosis of heart failure
  • Left ventricular ejection fraction \</=40%

Exclusion criteria

Exclusion Criteria:

  • Concomitant hypertension (blood pressure >150/90 mmHg on admission and at least twice more during the index stay)
  • Planned LVAD or Heart Transplant in next 3 months
  • Patient on current or planned renal dialysis
  • Inability to give the consent
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    Sodium Restricted Diet

    Low Salt (cardiac) diet

    Other: Sodium Restricted Diet

  • Active comparator
    Regular Diet

    Non-Cardiac diet

    Other: Regular Diet

Interventions

  • OtherSodium Restricted Diet

    Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)

  • OtherRegular Diet

    Non-Cardiac Diet, as defined by our Hospital Nutritional Services

06

What researchers measure

Primary outcomes

  1. Readmission Rate

    Number of hospital and ER admissions during the 1 year follow up period

    Time frame: 12 months

Secondary outcomes

  1. Length of stay

    number of days hospitalized

    Time frame: from time of hospital admission to hospital discharge, up to one year

  2. Total length of stay

    total days admitted to hospital during follow up period

    Time frame: 1 year follow up period

  3. Weight

    Time frame: measured daily during hospital admission period, up to one year

  4. NT-pro BNP, pg/mL

    Time frame: at the time of hospital admission and time of hospital discharge, up to one year

  5. Diet Satisfaction as assessed by the Diet Acceptability Questionnaire

    Time frame: at the time of hospital discharge (final hospitalization day, up to one year) and one year

07

Study locations

1 site
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02689635
Lead sponsor
Maya Guglin
Responsible party
Maya Guglin (Professor, Indiana University School of Medicine) — Sponsor-investigator
First posted
Feb 24, 2016
Start date
Nov 2016
Primary completion
Feb 2019
Completion
Feb 2019
Last update
Apr 22, 2021

Study contacts

Maya Guglin, MD, PhD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion